東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

FindBook

Google Book

Amazon

博客來

Enhanced Delivery of Antibody Therapy Using Focused Ultrasound in a Mouse Model of Parkinson's Disease.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Enhanced Delivery of Antibody Therapy Using Focused Ultrasound in a Mouse Model of Parkinson's Disease./
作者:	Murphy, Devin.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2021,
面頁冊數:	64 p.
附註:	Source: Masters Abstracts International, Volume: 83-04.
Contained By:	Masters Abstracts International83-04.
標題:	Medical imaging. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28719639
ISBN:	9798460409754

Enhanced Delivery of Antibody Therapy Using Focused Ultrasound in a Mouse Model of Parkinson's Disease.
Murphy, Devin.

Enhanced Delivery of Antibody Therapy Using Focused Ultrasound in a Mouse Model of Parkinson's Disease. - Ann Arbor : ProQuest Dissertations & Theses, 2021 - 64 p.

Source: Masters Abstracts International, Volume: 83-04.

Thesis (M.S.)--The University of Arizona, 2021.

This item must not be sold to any third party vendors.

Parkinson's Disease (PD) is the second-most prevalent neurodegenerative disorder after Alzheimer's Disease and affects 680,000 US adults over the age of 45 as of 2010 [Marras et al. 2018]. This disease results in a loss of dopaminergic neurons, specifically in the substantia nigra. PD has also been associated with the accumulation of toxic oligomeric variants of alpha-synuclein (a-syn). Although there are several medications that can help manage symptoms for PD, there is no cure. We have successfully created antibody reagents that selectively target toxic a-syn variants without binding to non-oligomeric forms of normal alpha-synuclein. However, the blood-brain barrier (BBB) is a major obstacle for drug delivery and treatment of PD due to its low permeability to foreign objects. Due to the size of the monoclonal antibody, it is unable to cross the BBB without transporter proteins or temporary disruption of the BBB. This antibody therapy is delivered using novel magnetic resonance guided focused ultrasound (MRgFUS) treatment, which transiently disrupts tight junctions between epithelial cells in the BBB, resulting in gaps large enough for the antibody therapy to cross the BBB. Results indicate that the BBB was successfully opened over multiple timepoints, and the procedure does not cause extensive tissue damage. The results also show that the targeted antibody selectively binds to toxic a-syn in regions of the brain where the BBB has been temporarily disrupted. Future work includes longitudinal studies to determine if this treatment combination can delay disease progression or improve quality of life in murine models of Parkinson's Disease.

ISBN: 9798460409754Subjects--Topical Terms:

3172799
Medical imaging.
Subjects--Index Terms:

Alpha-synuclein

Enhanced Delivery of Antibody Therapy Using Focused Ultrasound in a Mouse Model of Parkinson's Disease.
LDR:02831nmm a2200361 4500 001 2348080
005 20220906075200.5
008 241004s2021 ||||||||||||||||| ||eng d
020 $a 9798460409754
035 $a (MiAaPQ)AAI28719639
035 $a AAI28719639
040 $a MiAaPQ $c MiAaPQ
100 1 $a Murphy, Devin. $3 3687400
245 1 0 $a Enhanced Delivery of Antibody Therapy Using Focused Ultrasound in a Mouse Model of Parkinson's Disease.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2021
300 $a 64 p.
500 $a Source: Masters Abstracts International, Volume: 83-04.
500 $a Advisor: Trouard, Theodore P.
502 $a Thesis (M.S.)--The University of Arizona, 2021.
506 $a This item must not be sold to any third party vendors.
520 $a Parkinson's Disease (PD) is the second-most prevalent neurodegenerative disorder after Alzheimer's Disease and affects 680,000 US adults over the age of 45 as of 2010 [Marras et al. 2018]. This disease results in a loss of dopaminergic neurons, specifically in the substantia nigra. PD has also been associated with the accumulation of toxic oligomeric variants of alpha-synuclein (a-syn). Although there are several medications that can help manage symptoms for PD, there is no cure. We have successfully created antibody reagents that selectively target toxic a-syn variants without binding to non-oligomeric forms of normal alpha-synuclein. However, the blood-brain barrier (BBB) is a major obstacle for drug delivery and treatment of PD due to its low permeability to foreign objects. Due to the size of the monoclonal antibody, it is unable to cross the BBB without transporter proteins or temporary disruption of the BBB. This antibody therapy is delivered using novel magnetic resonance guided focused ultrasound (MRgFUS) treatment, which transiently disrupts tight junctions between epithelial cells in the BBB, resulting in gaps large enough for the antibody therapy to cross the BBB. Results indicate that the BBB was successfully opened over multiple timepoints, and the procedure does not cause extensive tissue damage. The results also show that the targeted antibody selectively binds to toxic a-syn in regions of the brain where the BBB has been temporarily disrupted. Future work includes longitudinal studies to determine if this treatment combination can delay disease progression or improve quality of life in murine models of Parkinson's Disease.
590 $a School code: 0009.
650 4 $a Medical imaging. $3 3172799
650 4 $a Biomedical engineering. $3 535387
653 $a Alpha-synuclein
653 $a Blood-brain barrier
653 $a Focused ultrasound
653 $a Magnetic resonance imaging
653 $a Parkinson's disease
690 $a 0574
690 $a 0541
710 2 $a The University of Arizona. $b Biomedical Engineering. $3 2092025
773 0 $t Masters Abstracts International $g 83-04.
790 $a 0009
791 $a M.S.
792 $a 2021
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28719639